The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

BACKGROUND: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of syn...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Colom-Cadena, Martí, Spires-Jones, Tara, Zetterberg, Henrik, Blennow, Kaj, Caggiano, Anthony, DeKosky, Steven T., Fillit, Howard, Harrison, John E., Schneider, Lon S., Scheltens, Phillip, de Haan, Willem, Grundman, Michael, van Dyck, Christopher H., Izzo, Nicholas J., Catalano, Susan M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053087/
https://ncbi.nlm.nih.gov/pubmed/32122400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00588-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars